Smoking cessation in patients with respiratory disease: Existing treatments and future directions

The Lancet Respiratory Medicine

Volumn 1, Issue 3, 2013, Pages 241-250

  Rigotti, Nancy A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CYTISINE; NICOTINE; NICOTINE VACCINE; NORTRIPTYLINE; PLACEBO; VARENICLINE;

BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG THERAPY; HEALTH CARE QUALITY; HEALTH SERVICE; HUMAN; LUNG CANCER; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SEIZURE; SMOKELESS TOBACCO; SMOKING; SMOKING CESSATION;

CAUSE OF DEATH; COST-BENEFIT ANALYSIS; DIRECTIVE COUNSELING; HUMANS; PREVENTIVE HEALTH SERVICES; PSYCHOTHERAPY, GROUP; RESPIRATORY TRACT DISEASES; SMOKING; SMOKING CESSATION; SOCIAL SUPPORT; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME;

EID: 84877134722     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70063-8     Document Type: Review

References (88)

1. Report on the global tobacco epidemic, 2008: the MPOWER package WHO, (accessed April 9, 2013). http://www.who.int/tobacco/mpower/mpower_report_full_2008.pdf.
2. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013, 368:341-350.
3. Celli BR, MacNee W Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946. ATS/ERS Task Force.
4. Tonnesen P, Carrozzi L, Fagerstrom KO, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J 2007, 29:390-417.
5. Clinical Guideline 12: Management of chronic obstructive pulmonary disease in adults in primary and secondary care National Institute for Clinical Excellence, (accessed April 9, 2013). http://www.nice.org.uk/nicemedia/pdf/CG012_niceguideline.pdf.
6. Varmus H, Kumar HS Addressing the growing international challenge of cancer: a multinational perspective. Sci Transl Med 2013, 5:175cm2.
7. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet 2007, 370:741-750. on behalf of the BOLD Collaborative Research Group.
8. Jha P, Jacob B, Gajalakshmi V, et al. A nationally representative case-control study of smoking and death in India. N Engl J Med 2008, 358:1137-1147.
9. Slama K, Chiang CY, Enarson DA, et al. Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. Int J Tuberc Lung Dis 2007, 11:1049-1061.
10. The health consequences of involuntary exposure to tobacco smoke: a report of the surgeon general US Department of Health and Human Services, (accessed April 9, 2013). http://www.surgeongeneral.gov/library/reports/secondhandsmoke/executivesummary.pdf.
11. Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 182:693-718.
12. The medical case for clean air in the home, at work and in public places: a report on passive smoking by the Tobacco Advisory Group of the Royal College of Physicians 2005, Royal College of Physicians, RCP, London.
13. Passive smoking and children: a report by the Tobacco Advisory Group 2010, Royal College of Physicians, RCP, London.
14. Doll R, Peto R, Boreham J, Sutherland I Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004, 328:1-9.
15. Pirie K, Peto R, Reeves GK, Green J, Beral V The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet 2013, 381:133-141. for the Million Women Study Collaborators.
16. Hogg JC Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004, 364:709-721.
17. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation on 14·5 year mortality. Ann Intern Med 2005, 142:233-239.
18. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline 2008, US Department of Health and Human Services, Public Health Service, Rockville.
19. Cochrane Tobacco Addiction Group, (accessed Jan 31, 2013). http://tobacco.cochrane.org/.
20. Whittaker R, McRobbie H, Bullen C, Borland R, Rodgers A, Gu Y Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev 2012, 11. CD006611.
21. Hughes JR, Stead LF, Lancaster T Antidepressants for smoking cessation. Cochrane Database Syst Rev 2011, 1. CD000031.
22. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012, 11. CD000146.
23. Cahill K, Stead LF, Lancaster T Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012, 4. CD006103.
24. Stead LF, Bergson G, Lancaster T Physician advice for smoking cessation. Cochrane Database Systematic Rev 2008, 2. CD000165.
25. Stead LF, Lancaster T Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev 2005, 2. CD001007.
26. Lancaster T, Stead LF Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005, 2. CD001292.
27. Gourlay SG, Stead LF, Benowitz N Clonidine for smoking cessation. Cochrane Database Syst Rev 2004, 3. CD000058.
28. Stead LF, Perera R, Lancaster T Telephone counselling for smoking cessation. Cochrane Database Syst Rev 2006, 3. CD002850.
29. Rigotti NA Strategies to help a smoker who is struggling to quit. JAMA 2012, 308:1573-1580.
30. Stead LF, Lancaster T Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev 2012, 10. CD008286.
31. White AR, Rampes H, Liu JP, Stead LF, Campbell J Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev 2011, 1. CD000009.
32. Barnes J, Dong CY, McRobbie H, Walker N, Mehta M, Stead LF Hypnotherapy for smoking cessation. Cochrane Database Syst Rev 2010, 10. CD001008.
33. Warnier MJ, van Riet EES, Rutten FH, De Bruin ML, Sachs APE Smoking cessation strategies in patients with COPD. Eur Respir J 2013, 41:727-734.
34. Bauld L, Bell K, McCullough L, Richardson L, Greaves L The effectiveness of NHS smoking cessation services: a systematic review. J Public Health 2010, 32:71-82.
35. The Health and Social Care Information Centre April, 2011-March, 2012, Statistics on NHS Stop Smoking Services, England, (accessed March 24, 2013). https://catalogue.ic.nhs.uk/publications/public-health/smoking/nhs-stop-smok-serv-eng-apr-2011-mar-2012/stat-stop-smok-serv-eng-apr-11-mar-12-rep.pdf.
36. Free C, Knight R, Robertson S, et al. Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. Lancet 2011, 378:49-55.
37. Abroms LC, Padmanabhan N, Thaweethai L, Phillips T iPhone apps for smoking cessation: a content analysis. Am J Prev Med 2011, 40:279-285.
38. Parkes G, Greenhalgh T, Griffin M, Dent R Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008, 336:598-600.
39. Buffels J, Degryse J, Decramer M, Heyrman J Spirometry and smoking cessation advice in general practice: a randomised clinical trial. Respir Med 2006, 100:2012-2017.
40. Stratelis G, Mölstad S, Jakobsson P, Zetterström O The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. Scand J Prim Health Care 2006, 24:133-139.
41. Kotz D, Wesseling G, Huibers MJH, van Schayck OCP Efficacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J 2009, 33:754-762.
42. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011, 155:179-191.
43. Stead LF, Lancaster T Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev 2012, 12. CD009670.
44. Tonnesen P, Mikkelsen K, Bremann L Nurse conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest 2006, 130:334-342.
45. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001, 357:1571-1575.
46. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011, 139:591-599.
47. Wagena EJ, Knipschild PG, Huibers MJ, et al. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 2005, 165:2286-2292.
48. Garrett BE, Rose CA, Henningfield JE Tobacco addiction and pharmacological interventions. Expert Opin Pharmacother 2001, 2:1548.
49. Rigotti NA Clinical practice: treatment of tobacco use and dependence. N Engl J Med 2002, 346:506-512.
50. Smith SS, McCarthy DE, Japuntich SJ, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med 2009, 169:2148-2155.
51. Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatr 2009, 66:1253-1262.
52. Shiffman S, Ferguson SG, Rohay J, Gitchell JG Perceived safety and efficacy of nicotine replacement therapies among US smokers and ex-smokers: relationship with use and compliance. Addiction 2008, 103:1371-1378.
53. Alpert HR, Connolly GN, Biener L A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation. Tob Control 2013, 22:32-37.
54. Hughes JR, Cummings KM, Foulds J, Shiffman S, West R Effectiveness of nicotine replacement therapy-a rebuttal. Addiction 2012, 107:1527-1528.
55. Borland R, Partos TR, Cummings KM Systematic biases in cross-sectional community studies may underestimate the effectiveness of stop-smoking medications. Nicotine Tob Res 2012, 14:1483-1487.
56. Christenhusz L, Pieterse M, Seydel E, et al. Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Educ Couns 2007, 66:162-166.
57. FDA requires new boxed warnings for the smoking cessation drugs chantix and zyban 2009, US Food and Drug Administration, Food and Drug Administration Public Health Advisory.
58. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296:56-63.
59. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55.
60. Aubin H-J, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008, 63:717-724.
61. FDA drug safety communication: safety review update of chantix (varenicline) and risk of neuropsychiatric adverse events US Food and Drug Administration, (accessed March 11, 2013). http://www.fda.gov/Drugs/DrugSafety/ucm276737.htm#References.
62. FDA drug safety communication: safety review update of chantix (varenicline) and risk of cardiovascular adverse events US Food and Drug Administration, (accessed March 10, 2013). http://www.fda.gov/Drugs/DrugSafety/ucm330367.htm.
63. Tonstad S, Davies S, Flammer M, Russ C, Hughes J Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010, 33:289-301.
64. Gunnell D, Irvine D, Wise L, Davies C, Martin RM Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009, 339:b3805.
65. Meyer TE, Taylor LG, Xie S, et al. Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System. Addiction 2013, 108:203-210.
66. Singh S, Loke YK, Spangler JG, Furberg CD Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011, 183:1359-1366.
67. Prochaska JJ, Hilton JF Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012, 344:e2856.
68. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: randomized trial. Circulation 2010, 121:221-229.
69. Svanstrom H, Pasternak B, Hviid A Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ 2012, 345:e7176.
70. Current cigarette smoking among adults-United States, 2011. MMWR Morb Mortal Wkly Rep 2012, 61:889-894. Centers for Disease Control and Prevention.
71. Ebbert JO, Croghan IT, Sood A, Schroeder DR, Hays JT, Hurt RD Varenicline and bupropion sustained release combination therapy for smoking cessation. Nicotine Tob Res 2009, 11:237-239.
72. Ebbert JO, Burke MV, Hays JT, Hurt RD Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res 2009, 11:572-576.
73. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006, 296:64-71. for the Varenicline Phase 3 Study Group.
74. Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized controlled trial. Ann Intern Med 2001, 135:423-433.
75. Steinberg MB, Greenhaus S, Schmelzer AC, et al. Triple-combination pharmacotherapy for medically ill smokers. Ann Intern Med 2009, 150:447-454.
76. Schnoll RA, Patterson F, Wileyto EP, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med 2010, 152:144.
77. Carpenter MJ, Jardin BF, Burris JL, et al. Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: a review of the literature. Drugs (in press).
78. Lindson-Hawley N, Aveyard P, Hughes JR Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst Rev 2012, 11. CD008033.
79. Ray R, Tyndale RF, Lerman C Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet 2009, 23:252-261.
80. Hartmann-Boyce J, Cahill K, Hatsukami D, Cornuz J Nicotine vaccines for smoking cessation. Cochrane Database Syst Rev 2012, 8. CD007072.
81. West R, Zatonski W, Cedzynska M, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011, 365:1193-1200.
82. Hajek P, McRobbie H, Myers K Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax 2013, published online Feb 12. 10.1136/thoraxjnl-2012-203035.
83. Quitting Smoking Among Adults-United States, 2001-2010. Morb Mortal Wkly Rep 2011, 60:1513-1519. Center for Disease Control and Prevention.
84. West R, Brown J Smoking and smoking cessation in England 2011: Findings from the Smoking Toolkit Study (accessed April 10, 2013). http://www.smokinginengland.info.
85. Public health draft guidance. Tobacco: harm-reduction approaches to smoking National Institute for Health and Clinical Excellence, (accessed April 9, 2013). http://guidance.nice.org.uk/PHG/52/Consultation/Latest.
86. King BA, Alam S, Promoff G, Arrazola R, Dube SR Awareness and ever use of electronic cigarettes among US adults, 2010-2011. Nicotine Tob Res 2013, published online Feb 28. 10.1093/ntr/ntt013.
87. Reda AA, Kotz D, Evers SM, van Schayck CP Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database Syst Rev 2012, 6. CD004305.
88. Rigotti NA, Clair C, Munafo MR, Stead LF Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev 2012, 5. CD001837.